Daratumumab e Elotuzumab: l'esperienza real world della REP

R. Miccolis U.O.C. Ematologia con Trapianto Barletta

Approved Antibodies

Elotuzumab

- mAb to SLAMF7
- Approved in combination with Len/Dex
- 1 to 3 prior therapies

Daratumumab

- mAb to CD38
- Approved as monotherapy ≥ 3 prior therapies
- Approved in combination with Len/Dex or Bor/Dex for patients who have had at least 1 prior line of therapy

Lonial S, et al. *N Engl J Med.* 2015;373:621-631; Lonial S, et al. *Lancet.* 2016;387:1551-1560; Lokhorst HM, et al. *N Engl J Med.* 2015;373:1207-1219; Palumbo A, et al. *N Engl J Med.* 2016;375:754-766; Dimopoulos MA, et al. *N Engl J Med.* 2016;375:1319-1331.

ELOQUENT-2

Len/Dex ± Elotuzumab



Elotuzumab: anti-SLAMF7 mAB

Primary End points: PFS and ORR

	Elotuzumab Lenalidomide Dexamethasone	Lenalidomide Dexamethasone	*P* Value
n	321	325	
Median PFS, mo	19.4	14.9	.0004
Median OS, mo	43.7	39.6	.0257
ORR, %	79	66	.0002

- Fatigue, pyrexia, diarrhea were the most common (any-grade) non-heme AE
- Grade 3/4 lymphopenia (77% vs 49%) more common with elotuzumab
- Infusion reactions occurred in 10% of patients

Dimopulos M, et al. *ASH Annual Meeting.* 2015;126:28.

ELOTUZUMAB

Numero centri	7
Tot pz	60
Età mediana (min-max)	77 (51-82)
Elo-RD in seconda linea	37
Precedente Lenalidomide	14 (?)
Elo-RD in corso	52
Recidive/progressioni	6
Interruzione per tossicità	2

ELOTUZUMAB

Tossicità G3-4	
Anemia	4
Neutropenia	**16**
Piastrinopenia	5
Gastroenterica	0
Astenia	2

Reazioni infusionali	**0**

ELOTUZUMAB

Migliore Risposta	
CR	0
VGPR	2
PR	13
SD	7

Non è stata effettuata valutazione della migliore risposta per tutti i pazienti

Approved Antibodies

Elotuzumab

- mAb to SLAMF7
- Approved in combination with Len/Dex
- 1 to 3 prior therapies

Daratumumab

- mAb to CD38
- Approved as monotherapy ≥ 3 prior therapies
- Approved in combination with Len/Dex or Bor/Dex for patients who have had at least 1 prior line of therapy

Lonial S, et al. *N Engl J Med.* 2015;373:621-631; Lonial S, et al. *Lancet.* 2016;387:1551-1560; Lokhorst HM, et al. *N Engl J Med.* 2015;373:1207-1219; Palumbo A, et al. *N Engl J Med.* 2016;375:754-766; Dimopoulos MA, et al. *N Engl J Med.* 2016;375:1319-1331.

Daratumumab (Dara) Monotherapy for Heavily Pretreated Relapsed/Refractory (R/R) Multiple Myeloma (MM)

- Combined analysis of 2 Phase II trials of 16 mg/kg dara for R/R MM:
  - MMY2002 (Sirius): N = 106 patients with ≥3 prior therapies including a proteasome inhibitor, an immunomodulatory drug (IMiD) or both
  - GEN501: N = 42 patients who experienced relapse after or whose MM was refractory to ≥2 prior therapies

Combined analysis	MMY2002 (n = 106)	GEN501 part 2 (n = 42)	Total (n = 148)
Overall response rate (ORR)	29.2%	35.7%	31.1%
Overall survival (OS) rate (1 year)	65%	77%	69%

Usmani S et al. *Proc ASH* 2015;Abstract 29.


A
Patients Progression-free and Alive (%)
100
80
60
40
20
0
Median PFS = 4.0 months (95% CI, 2.8-5.6)
0 2 4 6 8 10 12 14 16 18 20 22 24 26
Months from Start of Treatment
Patients at risk 148 91 61 48 29 15 13 10 7 6 4 3 2 0
B
Responders
MR/SD
PD/NE
Patients Progression-free and Alive (%)
100
75
50
25
0
Median PFS = 15.0 months
(95% CI, 7.4-NE)
Median PFS = 3.0 months
(95% CI, 2.8-3.7)
Median PFS = 0.9 months (95% CI, 0.9-1.0)
0 2 4 6 8 10 12 14 16 18 20 22 24 26
Months from Start of Treatment
Patients at risk
Responders 46 46 41 35 27 14 13 10 7 6 4 3 2 0
MR/SD 77 45 20 13 2 1 0 0 0 0 0 0 0 0
PD/NE 25 0 0 0 0 0 0 0 0 0 0 0 0 0

Daratumumab



ASH 2016 Abstracts 489, 1150, 1151

DARATUMUMAB

Centri	5
Tot pz	35
Età mediana	66 (40-77)
Daratumumab monoterapia	20
DaraVD	8
DaraRD	7
Daratumumab in corso	23
Cause sospensione	10 progressione 3 nn

Tutti i casi di sospensione per progressione riguardavano Daratumumab in monoterapia, solo una progressione in corso di Dara-VD

DARATUMUMAB

- Quasi tutti i pazienti hanno effettuato la prima infusione in regime di ricovero
- È stata riportata una sola reazione infusionale G3
- Nessuna infusione non è stata terminata per reazione infusionale
- Nessun trattamento è stato interrotto per tossicità

Grazie